Homocysteine Restricts Copper Availability Leading to Suppression of Cytochrome C Oxidase Activity in Phenylephrine-Treated Cardiomyocytes

Xiao Zuo1, Daoyin Dong1, Miao Sun1, Huiqi Xie1, Y. James Kang1,2*

1 Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China, 2 Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky, United States of America

Abstract
Cardiomyocyte hypertrophy induced by phenylephrine (PE) is accompanied by suppression of cytochrome c oxidase (CCO) activity, and copper (Cu) supplementation restores CCO activity and reverses the hypertrophy. The present study was aimed to understand the mechanism of PE-induced decrease in CCO activity. Primary cultures of neonatal rat cardiomyocytes were treated with PE at a final concentration of 100 μM in cultures for 72 h to induce cell hypertrophy. The CCO activity was determined by enzymatic assay and changes in CCO subunit COX-IV as well as copper chaperones for CCO (COX17, SCO2, and COX11) were determined by Western blotting. PE treatment increased both intracellular and extracellular homocysteine concentrations and decreased intracellular Cu concentrations. Studies in vitro found that homocysteine and Cu form complexes. Inhibition of the intracellular homocysteine synthesis in the PE-treated cardiomyocytes prevented the increase in the extracellular homocysteine concentration, retained the intracellular Cu concentration, and preserved the CCO activity. PE treatment decreased protein concentrations of the COX-IV, and the Cu chaperones COX17, COX11, and SCO2. These PE effects were prevented by either inhibition of the intracellular homocysteine synthesis or Cu supplementation. Therefore, PE-induced elevation of homocysteine restricts Cu availability through its interaction with Cu and suppression of Cu chaperones, leading to the decrease in CCO enzyme activity.

Citation: Zuo X, Dong D, Sun M, Xie H, Kang YJ (2013) Homocysteine Restricts Copper Availability Leading to Suppression of Cytochrome C Oxidase Activity in Phenylephrine-Treated Cardiomyocytes. PLoS ONE 8(6): e67549. doi:10.1371/journal.pone.0067549

Introduction
Disturbance in the mitochondrial structure and metabolism makes a critical contribution to the pathogenesis of hypertrophic cardiomyopathy [1–3]. Among the essential components involved in the mitochondrial integrity and function, cytochrome c oxidase (CCO) is the last of the three proton-pumping assemblies of the mitochondrial respiratory chain, catalyzing the transfer of electron from reduced cytochrome c to molecular oxygen, the final electron acceptor. Both experimental and clinical studies demonstrated the determinant role of CCO depression in the initiation and progression of cardiac hypertrophy and dysfunction [4–6]. CCO is composed of 13 subunits, three of which (COX-I, -II, and -III) are encoded by the mitochondrial DNA and the rest are encoded by the nuclear DNA [7–9]. In these subunits, COX-I and COX-II contain copper (Cu) active sites and constitute the catalytic core of CCO [10]. In rodent models, Cu deficiency decreases the level of CCO subunit proteins and inhibits the CCO activity [11–13]. Cu chaperones for CCO, including cytochrome c oxidase assembly homolog 17 (COX17) and 11 (COX11), cytochrome oxidase-deficient homolog 1 (SCO1) and 2 (SCO2), are responsible for delivering Cu to the Cu active sites Cu4 on COX-II and Cu4 on COX-I in CCO [14–17]. Mutations in either SCO1 or SCO2 cause severe CCO assembly impairment and thus decrease the CCO activity [18,19]. Loss of function of COX17 attenuates the delivery of Cu to SCO1 and COX11, and inhibits the CCO activity [20,21]. Mutations in COX11 also suppress the CCO activity [22]. Cu concentrations decrease in pressure overload-induced hypertrophic hearts [23]. Dietary Cu supplementation restores Cu levels in the heart, recovers the CCO activity, and reverses hypertrophic cardiomyopathy in mouse model subjected to pressure overload [23]. In primary cultures of neonatal rat cardiomyocytes, exposure to phenylephrine (PE) causes depression in the CCO activity and cell hypertrophy. Addition of Cu to the culture recovers the CCO activity and reverses the hypertrophy [24]. It is thus concluded that the limitation of Cu availability to the CCO under the condition of either pressure overload [23] or PE treatment [24] is responsible for the depressed CCO activity. However, the mechanism by which Cu restriction takes place in the hypertrophic cardiomyocytes remains elusive.

Pressure overload increases cardiac homocysteine production [25]. Experimental and clinical studies produced supporting evidence that elevated blood levels of homocysteine are linked to increased risk of cardiovascular diseases [26–28]. The increase in the blood concentrations of homocysteine is associated with an increase in blood Cu concentrations [27–29]. Studies in vitro found that Cu and homocysteine form complexes, which elicit remark-
able changes in the atherogenic activity in the cultured endothelial cells [30-32].

The present study was undertaken to specifically address the link between homocysteine and the restriction of Cu availability to CCO in PE-induced hypertrophic cardiomyocytes. To provide a comprehensive understanding, the effect of Cu restriction on Cu chaperones for CCO and on a critical subunit of CCO assembly, COX-IV, was determined. The results demonstrated that the interaction between Cu and homocysteine and the depression of Cu chaperones for CCO restrict the availability of Cu to the CCO, leading to the suppression of its enzymatic activity.

Methods

Cell Culture

Primary cultures of neonatal rat cardiomyocytes were established according to a procedure published previously [33]. Briefly, the hearts exercised from 1–3 day-old Sprague–Dawley rats were cut into 1.0 mm and digested with collagenase II (GIBCO, USA) and Trypsin (TN, GIBCO, USA) for 5 min, repeating 6 times. The animal procedure was approved by the Institutional Animal Care and Use Committee of Sichuan University. The heart tissue digests were suspended in H-DMEM (GIBCO, USA) supplemented with antibiotics (GIBCO, USA) and 10% fetal bovine serum (FBS, Hyclone). Fibroblasts were removed by pre-incubation for 1 h at 37°C. The cardiomyocytes in suspension were collected and seeded in 6-well-plate containing H-DMEM supplemented with 10% FBS, BrdU (Roche, USA) and antibiotics for 24 h before subsequent experiments. The purity of cardiomyocytes in cultures was determined by flow cytometry quantitative analysis of the cells labeled with fluorescent antibody for α-sarcomeric actin (Santa Cruz, USA), which was more than 90%.

Experimental procedure

Cardiomyocyte hypertrophy was induced according to a previous publication [34], with some modifications. Briefly, primary cultures of neonatal rat cardiomyocytes were treated with phenylephrine (PE, Sigma-Aldrich) at a final concentration of 100 μM in cultures for 24 h before subsequent experiments. The purity of cardiomyocytes in cultures was determined by flow cytometry quantitative analysis of the cells labeled with fluorescent antibody for α-sarcomeric actin (Santa Cruz, USA), which was more than 90%.

Determination of Cu concentrations

Intracellular Cu concentrations were determined with graphite furnace atomic absorption spectrophotometer (AAS). Briefly, cells were collected by cell scraper, washed twice with 1% SDS-buff ered solution. Protein samples were mixed with 5× loading buffer, boiled for 10 min at 100°C and cooled. Equal amounts of protein (50–100 μg) from each sample were separated by 12% SDS-PAGE. Proteins were then electrophoretically transferred to a polyvinylidene fluoride membrane (Bio-Rad, USA). Transferred proteins were blocked with 5% non-fat dry milk in Tris-HCl buffer solution containing Tris-HCl (50 mM), NaCl (150 mM), and Tween-20 (0.1%) (TBS-T) for 1 h at room temperature. The blots were then incubated with respective primary antibodies (anti-COX17, anti-COX11, anti-COX2, Santa Cruz, USA; anti-SCO2, Abcam, USA) in blocking solution according to the vendor’s recommendations. After incubation, the blots were washed with TBS-T six times for 5 min each. The blots were incubated for 2 h with appropriate secondary antibody. After washing six times (5 min each), target proteins were visualized using chemiluminescence (Bio-rad, USA) and analyzed by densitometry using a Quantity One Software.
Statistical analysis

Data were obtained from three separate experiments and expressed as means ± S.E.M. A multiple factorial design was applied to this study. After a significant interaction was detected by the analysis of variance (ANOVA), the significance of the main effects was further determined by F-test. The level of significance was considered when \( P<0.05 \).

Results

PE-induced elevation of the intracellular and extracellular homocysteine concentrations

Cardiomyocyte hypertrophy, measured by cell size, cellular protein contents, molecular markers of the hypertrophy, was observed in the primary cultures of neonatal rat cardiomyocytes treated with 100 \( \mu \)M PE for 48 hrs (Supplement 1). In the hypertrophic cardiomyocytes, homocysteine levels were significantly increased (Fig 1A). A parallel increase in the extracellular homocysteine concentrations was observed, as determined by the elevation of homocysteine concentrations in the culture media (Fig 1B). Homocysteine concentrations in the stock media were undetectable and in the media obtained from cultures without PE treatment were 1.2 \( \mu \)mol/L and increased to 2.2 \( \mu \)mol/L after PE treatment. With the increase in both intracellular and extracellular homocysteine concentrations, the intracellular Cu concentrations were significantly decreased (Fig 1C). Addition of Adox, which inhibits S-adenosyl-L-homocysteine hydrolase (SAHH) in homocysteine synthesis, significantly reduced both intracellular (Fig 1A) and extracellular (Fig 1B) homocysteine concentrations, and blocked the PE-induced elevation. The inhibition of the intracellular homocysteine synthesis prevented PE-induced decrease in the intracellular Cu concentrations (Fig 1C).

The effect of inhibition of homocysteine synthesis on PE-induced CCO depression

In the PE-treated cardiomyocytes, the CCO activity was significantly depressed, as shown in Fig 2. Addition of SAHH inhibitor Adox alone did not significantly affect the CCO activity, but blocked PE-induced depression of the CCO activity in the primary cultures of neonatal rat cardiomyocytes.

PE decreased protein levels of CCO subunit COX-IV as well as Cu chaperones COX17, COX11, and SCO2

To understand the molecular mechanism by which homocysteine suppresses the CCO activity, the protein concentrations of COX17, COX11, SCO2, and COX-IV were measured by Western blot analysis. The data presented in Fig 3 showed that PE significantly reduced the concentrations of all the proteins measured. Although the SAHH inhibitor Adox did not affect the concentrations of these proteins, it prevented their reduction by PE treatment.

![Figure 1. PE-induced changes in the intracellular (A) and extracellular homocysteine concentrations (B), and changes in the intracellular Cu concentrations (C) in primary cultures of neonatal rat cardiomyocytes. The cells were cultured in 10% FBS media for 24 h before medium change to serum-free media. The cells were then cultured for 72 h (Control), in the presence of 100 \( \mu \)M PE (PE), 1 \( \mu \)M Adox (Adox), or both PE and Adox (PE+Adox). The data were obtained from three independent experiments, and each experiment contains triplicate samples for each treatment. Values are means ± SEM. * or # significantly different from control group and # significantly different from PE-treated group (\( P<0.05 \)). doi:10.1371/journal.pone.0067549.g001](#)

![Figure 2. Changes in the CCO activity in the PE-treated primary cultures of neonatal rat cardiomyocytes. The cells were cultured and treated as the same as described for Fig 1. The data were obtained from three independent experiments, and each experiment contains triplicate samples for each treatment. Values are means ± SEM. * significantly different from control group (\( P<0.05 \)). doi:10.1371/journal.pone.0067549.g002](#)
Cu supplement prevented PE-induced depression of COX17, COX11, SCO2, and COX-IV

To determine whether the suppression by homocysteine of the CCO activity acts through the restriction of Cu availability, the cell cultures were supplemented with CuSO₄. The addition of a final concentration of Cu element at 5 μM in the culture completely blocked the PE-induced reduction in the protein concentrations of CCO assembly subunit COX-IV and Cu chaperones COX17, COX11 and SCO2 (Fig 4).

Discussion

The results presented here specifically addressed the mechanism by which PE treatment suppresses the CCO activity in cardiomyocytes. Cu is required for the CCO activity, and conversely, Cu deficiency leads to the suppression of the CCO activity [11–13]. In pressure overload-induced hypertrophic hearts and in PE-induced hypertrophic cardiomyocytes, Cu supplementation recovers the suppressed CCO activity and reverses the hypertrophy [23,24]. Therefore, it is conclusive that Cu limitation results in suppression in the CCO activity in hypertrophic cardiomyocytes. However, there are two specific questions that have not been addressed: (1) how does Cu restriction take place in the hypertrophic cardiomyocytes, and (2) what is the molecular basis for the suppression of the CCO activity?

In the present study, we found that PE treatment resulted in an enhanced production of homocysteine in the cultured neonatal rat cardiomyocytes, leading to increases in both intracellular and extracellular concentrations of homocysteine. On equal cell number basis, the extracellular homocysteine concentrations were 100 fold higher than the intracellular concentrations. The level of homocysteine in the stock media was undetectable, thus, the...
extracellular concentrations were likely exported from the cells. This was strongly supported by the fact that inhibition of the intracellular homocysteine synthesis by using the SAHH inhibitor Adox reduced the extracellular concentrations of homocysteine to the level even below that found in the culture media without PE treatment.

The increase in the intracellular homocysteine was accompanied by a decrease in the intracellular Cu concentrations. The link between these two events was revealed by the prevention of the decrease in Cu concentrations by the inhibition of homocysteine synthesis in the PE-treated cardiomyocytes. This thus suggests that the reduction in Cu concentrations and its availability is related to the enhanced homocysteine production. How does homocysteine limit the availability of intracellular Cu? There are reports demonstrating the formation of Cu and homocysteine complexes in in vitro studies [30-32]. We also detected the Cu-homocysteine complexes when they were mixed in vitro in another study (unpublished). This, in combination with the result above, answers the first question, i.e., PE-induced elevation of intracellular homocysteine concentrations is responsible for Cu restriction in the hypertrophic cardiomyocytes.

The suppression of the CCO activity in the PE-induced hypertrophic cardiomyocytes resulted from the elevation of intracellular homocysteine. This was demonstrated by the fact that the inhibition of homocysteine synthesis blocked the suppression by PE treatment of the CCO activity. What is the molecular basis for the suppression of the CCO activity? The assembly of the 13 subunits of CCO is an important process for the activation of the enzyme. How does homocysteine limit the availability of intracellular Cu? There are reports demonstrating the formation of Cu and homocysteine complexes in in vitro studies [30-32]. We also detected the Cu-homocysteine complexes when they were mixed in vitro in another study (unpublished). This, in combination with the result above, answers the first question, i.e., PE-induced elevation of intracellular homocysteine concentrations is responsible for Cu restriction in the hypertrophic cardiomyocytes.

Figure 4. Immunoblots of COX17, COX11, SCO2 and COX-IV proteins from the PE treated primary cultures of neonatal rat cardiomyocytes. Control (cultured for 72 h with non-PE or other treatment), PE (PE treated for 72 h), Cu (cultured without treatment for 48 h then treated with Cu for 24 h), and PE+Cu (PE treated for 48 h followed by Cu treatment for 24 h). The bar graphs show the quantitative analysis of the intensity of immunoblots by densitometry. Values are means ± SEM. * significantly different from control group (P<0.05).

doi:10.1371/journal.pone.0067549.g004
the availability of Cu to the Cu active sites. However, this restriction apparently is only one factor responsible for the suppressed CCO activity. The results presented in this study demonstrated that the impairment of the CCO assembly due to the reduction of COX-IV subunit would be another determinant factor. Inhibition of the disturbance of Cu transfer to Cu active sites in the CCO due to the reduction of the Cu chaperones COX17, COX11, and SCO2 would worsen the impairment of the CCO assembly. The contribution of the impairment of the CCO assembly to the suppressed CCO activity was further confirmed by the results that the inhibition of homocysteine synthesis prevented the reduction of COX-IV, COX17, COX11, and SCO2, and preserved the CCO activity. Therefore, the answer to the second question is that the suppressed CCO activity results at least in part from the impaired assembly of the holo-CCO.

How does the elevation of homocysteine affect the CCO assembly? We hypothesized that the restriction of Cu availability is responsible for the observed effect of homocysteine on the CCO assembly. To test this, we added physiologically relevant levels of Cu to the PE-treated cultures to examine the effect of Cu supplementation on PE-reduced concentrations of proteins involved in the CCO assembly. Under this condition, the elevation of homocysteine would not be affected, but the availability of Cu would be increased. The data obtained showed that Cu supplementation prevented the reduction of COX-IV, COX17, COX11, and SCO2 protein concentrations along with the preservation of the CCO activity. These results thus indicate that the reduced Cu availability or the Cu restriction is responsible for the suppressed CCO assembly induced by the elevation of homocysteine concentrations.

We speculate that the interaction between Cu and homocysteine, or the formation of Cu and homocysteine complexes is responsible for the restriction of Cu availability. This was also proposed in an early study examining homocysteine-induced CCO depression and apoptosis in neural cells [36], which stated that the binding of Cu and homocysteine would be responsible for the adverse effects of homocysteine. Although the formation of Cu and homocysteine complexes has been detected in in vitro studies, it is important to detect these complexes in vivo in future studies.

A limitation of the present study is that the mechanism by which PE treatment increases homocysteine production remains unknown. One of the pathways for the metabolism of homocysteine is its transsulfuration catalyzed by cystathionine β-synthase to become cystathionine, which in turn is converted to cysteine and α-ketobutyrate by cystathionine γ-hyase. It has been shown that oxidative inhibition of cystathionine β-synthase occurs, leading to accumulation of intracellular homocysteine [37]. Previous studies have demonstrated the production and accumulation of reactive oxygen species PE in cardiomyocytes [38]. Therefore, it is possible that PE-induced increase of homocysteine concentrations may result from the oxidative inhibition of the cystathionine β-synthase, which will be determined in our future studies.

In conclusion, the present study addressed the role of homocysteine in PE-suppressed CCO activity in hypertrophic cardiomyocyte. Homocysteine restricts the availability of intracellular Cu through its interaction with Cu and the suppression of Cu chaperones for CCO and CCO assembly subunits, leading to inhibition of the CCO activity. Conversely, inhibition of intracellular homocysteine synthesis results in preservation of the CCO activity and prevention of the subsequent adverse effects.

Supporting Information

Figure S1 PE-induced cell hypertrophy in primary cultures of neonatal rat cardiomyocytes. The cells were cultured in 10% FBS media for 24 h before medium change to serum-free media, culturing for 72 h. (A) Analysis of cell size by flow cytometry with a representative histogram and quantitative measurement. Control (non-treated and incubated for 72 h), PE (PE treated for 72 h). (B) Changes in total protein concentrations, normalized by cell number. (C) Changes in the expression of β-MHC, α-SA, and ANP, measured by real-time RT-PCR. Each group of data was obtained from three independent experiments, and each experiment contains triplicate samples for each treatment. Values are means ± SEM. *significantly different from control group (P<0.05).

Author Contributions

Conceived and designed the experiments: YJK. Performed the experiments: XZ DD MS. Analyzed the data: XZ YJK. Contributed reagents/materials/analysis tools: HX. Wrote the paper: YJK XZ.

References

1. Ohyashiki T, Hattori K, Sugiyama S, Tanaka M, Tanaka T, et al. (1992) Point mutations in mitochondrial DNA in patients with hypertrophic cardiomyopathy. Amer Heart J 124: 1260–1269.
2. Lucas DT, Pratulla A, Luke BS, Walter JK, Leslie AL (2003) Alterations in mitochondrial function in a mouse model of hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol 284: H575–H583.
3. Fassone E, Taanman Jan-Willem, Hargreaves IP, Sebire NJ, Cleary MA, et al. (2011) Mutations in the mitochondrial complex I assembly factor NDUFAP1 cause fatal infantile hypertrophic cardiomyopathy. J Med Genet 48: 491–497.
4. Zevelin M, Van Dyke DH, Servidei S, Bauserman SC, Bonilla E, et al. (1968) Myopathy and fatal cardiopathy due to cytochrome c oxidase deficiency. Arch Neurol 43: 1198–1202.
5. Radford NB, Wan B, Richman A, Szczepaniak LS, Li JL, et al. (2002) Cardiac nuclear encoded cytochrome c oxidase deficiency in mice lacking cytochrome-c oxidase subunit VIaH. Am J Physiol 283: C2314–C2320.
6. Medeiros DM, Shiry L, Samelman T (1997) Cardiac nuclear encoded cytochrome c oxidase subunits from rat hearts. Comp Biochem Physiol Pt B 111: 61–67.
7. Hejna M, Patin MA, Roques BP, Ressmann H, Schreiber V, et al. (1998) Cardiac nuclear-encoded cytochrome c oxidase subunits are decreased with copper restriction but not iron restriction: gene expression, protein synthesis and heat shock protein aspects. Comp Biochem Physiol Pt A 117: 77–87.
8. Takahashi Y, Kako K, Kashiwabara S, Takehara A, Inada Y, et al. (2002) Mammalian copper chaperone Cox17p has an essential role in activation of cytochrome c oxidase and embryonic development. Mol Cell Biol 21: 7614–7621.
9. Leary SC, Kaufman BA, Pellecchia G, Guerini GH, Mattman A, et al. (2004) Human SCO1 and SCO2 have independent, cooperative functions in copper delivery to cytochrome c oxidase. Hum Mol Genet 13: 1839–1848.
10. Tsuchihara T, Aoyama H, Yamashita E, Tomizaki T, Yamaguchi H, et al. (1995) Structures of metal sites of oxidized bovine heart cytochrome c oxidase at 28 A. Science 269: 1069–1074.
11. Takahashi Y, Kako K, Kashiwabara S, Takehara A, Inada Y, et al. (2002) Mammalian copper chaperone Cox17p has an essential role in activation of cytochrome c oxidase and embryonic development. Mol Cell Biol 21: 7614–7621.
12. Leary SC, Kaufman BA, Pellecchia G, Guerini GH, Mattman A, et al. (2004) Human SCO1 and SCO2 have independent, cooperative functions in copper delivery to cytochrome c oxidase. Hum Mol Genet 13: 1839–1848.
13. Leary SC, Cobine PA, Kaufman BA, Guerini GH, Mattman A, et al. (2007) The human cytochrome c oxidase assembly factors SCO1 and SCO2 have regulatory roles in the maintenance of cellular copper homeostasis. Cell Metab 5: 9–20.
10. Valnot I, Osman S, Gigarel N, Mchaye R, Amiel J, et al. (2000) Mutations of the Sco1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal onset hepatic failure and encephalopathy. Am J Hum Genet 67: 1104–1109.

11. Stiburek L, Vesela K, Hansikova H, Pecina P, Tesarova M, et al. (2005) Tissue-specific cytochrome c oxidase assembly defects due to mutations in SCO2 and SURF1. Biochem J 392: 623–632.

12. Horng YC, Cobine PA, Maxfield AB, Carr HS, Winge DR (2004) Specific copper transfer from the Cox17 metallochaperone to both Sco1 and Cox11 in the assembly of yeast cytochrome c oxidase. J Biol Chem 279: 35334–35340.

13. Oswald G, Krause-Buchholz U, Rodel G (2009) Knockdown of human COX17 affects assembly and supramolecular organization of cytochrome c oxidase. J Mol Biol 389: 470–479.

14. Tzagoloff A, Capitanio N, Nobrega MP, Gatti D (1990) Cytochrome oxidase assembly in yeast requires the product of COX11, a homolog of the P. denitrificans protein encoded by ORF3. EMBO J 9(9): 2759–2766.

15. Jiang Y, Reynolds C, Xiao C, Fong W, Zhou Z, et al. (2007) Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Exp Med 204: 657–666.

16. Zuo X, Xie H, Dong D, Jiang N, Zhu H, Kang YJ (2010) Cytochrome c oxidase is essential for copper-induced regression of cardiomyocyte hypertrophy. Cardiovasc Toxicol 10: 208–215.

17. Hughes WM Jr, Rodriguez WE, Rosenberger D, Chen J, Sun U, et al. (2008) Role of copper and homocysteine in pressure overload heart failure. Cardiovasc Toxicol 8(3): 137–44.

18. Malinow MR, Botson AG, Krauss RM (1990) Homocysteine, diet, and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 91(3): 176–182.

19. Mancoo MA, Bergmark C, Haswell SJ, Savage IF, Evans PH, et al. (2000) Correlation between plasma total homocysteine and copper in patients with peripheral vascular disease. Clin Chem 46(3): 385-391.

20. Jeremy JY, Shukla N, Angelini GD, Day A, Wan IYP, et al. (2002) Sustained increases of plasma homocysteine, copper, and serum ceruloplasmin after coronary artery bypass grafting. Ann Thorac Surg 74(3): 1553–1557.

21. Shukla N, Angelini GD, Jeremy JY (2007) Interactive effects of homocysteine and copper on angiogenesis in porcine isolated saphenous vein. Ann Thorac Surg 84: 45–49.

22. Apostolova MD, Botinchev PR, Ivanova BB, Russell WR, Mehandjiev DR, et al. (2003) Copper-homocysteine complexes and potential physiological actions. J Inorg Biochem 95(4): 321–333.

23. Carrasco-Pozo C, Alvarez-Larje A, Odra-Azar C, Lopez-Alarcon C, Speisky H (2006) In vitro interaction between homocysteine and copper ions: potential reoxidation implications. Exp Biol Med 231(9): 1369–1375.

24. Emsley AM, Jeremy JY, Gomes GN, Angelini GD, Plane F (1999) Investigation of the inhibitory effects of homocysteine and copper on nitric oxide-mediated relaxation of rat isolated aorta. Brit J Pharmacol 126(4): 1034–1040.

25. Hoffmann P, Richards D, Heinroth-Hoffman I, Mathias P, Wey H, et al. (1995) Arachidionic acid disrupts calcium dynamics in neonatal rat cardiac myocytes. Cardiovasc Res 30: 819–828.

26. Sudhikru RA, Shaiukh SR, Kovacs R, Stilwell W, Zaloga G (2004) Inhibition of phenylephrine-induced cardiac hypertrophy by docosahexaenoic acid. J Cell Biochem 92: 1141–1159.

27. Garcia AJ, Apitz-Castro R (2002) Plasma total homocysteine quantification: an improvement of the classical high-performance liquid chromatographic method with fluorescence detection of the thiol-SBD derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 779: 539–63.

28. Streck EL, Matte C, Veira PS, Calagnotto T, Wannamacher CM, et al. (2003) Impairment of energy metabolism in hippocampus of rats subjected to chemically-induced hyperhomocysteinemia. Biochim Biophys Acta 1637: 107–192.

29. Celano L, Gil M, Garballal S, Duran R, Dencola A, et al. (2009) Inactivation of cystathionine β-synthase with peroxynitrite. Arch Biochem Biophys 491(1-2): 96-105.

30. Lu YM, Han F, Shioda N, Moriguchi S, Shirasaki Y, et al. (2009) Phenylenediamine-induced cardiomyocyte injury is triggered by superoxide generation through uncoupled endothelial nitric-oxide synthase and ameliorated by 3-[3-[4-3-chloro-2-methylphenyl]-1-piperazinyl[ethyl]-5,6-dimethoxyindazole (DY-9836), a novel calmodulin antagonist. Mol Pharmacol 75: 101–112.